We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
Read MoreHide Full Article
On Mar 6, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The company has been expanding customer base through strategic buyouts. Moreover, the Personal Care segment has been growing strong and stable on the latest integrated tuck-in acquisitions. The stock carries a Zacks Rank #2 (Buy).
This renowned home health and hospice services provider has been outperforming its industry over the past six months. The stock has rallied 13.8% compared with the industry’s 1.7% gain.
We are upbeat about Amedisys’ strategic acquisitions over the past year. In this regard, the latest buyout has been that of Intercity Home Care, a personal care provider headquartered in Malden, MA. Notably, Intercity Home Care’s entire asset base has been taken over by Amedisys’ subsidiary, Associated Home Care.
With this, the renowned home health and hospice services provider have a wider presence in Massachusetts. Intercity Home Care has presence in across Greater Boston, North Shore and Merrimack Valley communities. Management believes that the company has enough cash to execute more such acquisitions in the days ahead.
We are also encouraged by the stabilization of the company’s Personal Care business, which has also been gaining from the recently integrated tuck-in acquisitions. Amedisys is looking forward to cashing in on the huge prospects in this segment. Moreover, the company is working on expanding the geographical presence of the Personal Care business.
We are also optimistic about the recently passed Bipartisan Budget Act of 2018 by the Congress, which reduces the company’s 2018 reimbursement impact from 1.4% to 0.7%.
Furthermore, the company has a long-term strategy to evolve from a traditional home health and hospice care company to one that is focused on bringing home a continuum of care. This is because Amedisys intends to better serve patients and diversify sources of payment so as to become less reliant on Medicare. In this regard, the company witnessed encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in the last reported quarter.
Meanwhile, escalating operating expenses and declining gross margin continue to raise concerns.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , PetMed Express (PETS - Free Report) and PerkinElmer .
PetMed has a long-term expected earnings growth rate of 10% and a Zacks Rank #1.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Image: Bigstock
Amedisys (AMED) Strong on Buyouts & Solid Personal Care Unit
On Mar 6, we issued an updated research report on Amedisys, Inc. (AMED - Free Report) . The company has been expanding customer base through strategic buyouts. Moreover, the Personal Care segment has been growing strong and stable on the latest integrated tuck-in acquisitions. The stock carries a Zacks Rank #2 (Buy).
This renowned home health and hospice services provider has been outperforming its industry over the past six months. The stock has rallied 13.8% compared with the industry’s 1.7% gain.
We are upbeat about Amedisys’ strategic acquisitions over the past year. In this regard, the latest buyout has been that of Intercity Home Care, a personal care provider headquartered in Malden, MA. Notably, Intercity Home Care’s entire asset base has been taken over by Amedisys’ subsidiary, Associated Home Care.
With this, the renowned home health and hospice services provider have a wider presence in Massachusetts. Intercity Home Care has presence in across Greater Boston, North Shore and Merrimack Valley communities. Management believes that the company has enough cash to execute more such acquisitions in the days ahead.
We are also encouraged by the stabilization of the company’s Personal Care business, which has also been gaining from the recently integrated tuck-in acquisitions. Amedisys is looking forward to cashing in on the huge prospects in this segment. Moreover, the company is working on expanding the geographical presence of the Personal Care business.
We are also optimistic about the recently passed Bipartisan Budget Act of 2018 by the Congress, which reduces the company’s 2018 reimbursement impact from 1.4% to 0.7%.
Furthermore, the company has a long-term strategy to evolve from a traditional home health and hospice care company to one that is focused on bringing home a continuum of care. This is because Amedisys intends to better serve patients and diversify sources of payment so as to become less reliant on Medicare. In this regard, the company witnessed encouraging growth in Medicare and non-Medicare revenues at the Home Health and Hospice divisions in the last reported quarter.
Meanwhile, escalating operating expenses and declining gross margin continue to raise concerns.
Other Key Picks
Other top-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , PetMed Express (PETS - Free Report) and PerkinElmer .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
PetMed has a long-term expected earnings growth rate of 10% and a Zacks Rank #1.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2.
Breaking News: Cryptocurrencies Now Bigger than Visa
The total market cap of all cryptos recently surpassed $700 billion – more than a 3,800% increase in the previous 12 months. They’re now bigger than Morgan Stanley, Goldman Sachs and even Visa! The new asset class may expand even more rapidly in 2018 as new investors continue pouring in and Wall Street becomes increasingly involved.
Zacks has just named 4 companies that enable investors to take advantage of the explosive growth of cryptocurrencies via the stock market.
Click here to access these stocks>>